MAPT and Alzheimer disease: It interacts with extracellular form tau aggregate, which makes it’s action independent on cellular entry; thus an major advantage.79,138 It was shown to stop tau seeding and trans-neuronal propagation in animal models, and thus potentially stop the progression of AD.79 The drug is currently in phase II trials in a study that recruits 400 patients with confirmed AD.139 The study will compare three doses of C2N8E12 to placebo, all given over a span of 2 years.